Suppr
超能文献

First AAV gene therapy poised for landmark approval.

作者信息

Smalley Eric

出版信息

Nat Biotechnol. 2017 Nov 9;35(11):998-999. doi: 10.1038/nbt1117-998.

DOI:10.1038/nbt1117-998

PMID:29121014

Abstract

摘要

相似文献

First AAV gene therapy poised for landmark approval.

Nat Biotechnol. 2017 Nov 9;35(11):998-999. doi: 10.1038/nbt1117-998.

Emerging Gene Therapy Treatments for Inherited Retinal Diseases.

Ophthalmic Surg Lasers Imaging Retina. 2018 Jul 1;49(7):472-478. doi: 10.3928/23258160-20180628-02.

Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.

Med Lett Drugs Ther. 2018 Mar 26;60(1543):53-55.

Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.

Mol Ther. 2021 Feb 3;29(2):442-463. doi: 10.1016/j.ymthe.2020.11.029. Epub 2020 Dec 3.

Quantitative Autofluorescence Following Gene Therapy With Voretigene Neparvovec.

JAMA Ophthalmol. 2020 Aug 1;138(8):919-921. doi: 10.1001/jamaophthalmol.2020.2018.

Bilateral Subretinal Voretigene Neparvovec-rzyl (Luxturna) Gene Therapy.

Ophthalmol Retina. 2019 May;3(5):450. doi: 10.1016/j.oret.2019.02.007.

The new landscape of retinal gene therapy.

Am J Med Genet C Semin Med Genet. 2020 Sep;184(3):846-859. doi: 10.1002/ajmg.c.31842. Epub 2020 Sep 5.

Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.

Mol Ther. 2018 Jan 3;26(1):256-268. doi: 10.1016/j.ymthe.2017.09.014. Epub 2017 Sep 19.

[RPE65-retinal Dystrophies: From the Spectrum of the Clinical Picture to Gene Therapy].

Klin Monbl Augenheilkd. 2024 Mar;241(3):257-258. doi: 10.1055/a-2237-7300. Epub 2024 Mar 20.

Gene therapy for eye as regenerative medicine? Lessons from RPE65 gene therapy for Leber's Congenital Amaurosis.

Int J Biochem Cell Biol. 2014 Nov;56:153-7. doi: 10.1016/j.biocel.2014.09.022. Epub 2014 Oct 5.

引用本文的文献

Trends and challenges of AAV-delivered gene editing therapeutics for CNS disorders: Implications for neurodegenerative disease.

Mol Ther Nucleic Acids. 2025 Jul 17;36(3):102635. doi: 10.1016/j.omtn.2025.102635. eCollection 2025 Sep 9.

Evaluation of subretinally delivered Cas9 ribonucleoproteins in murine and porcine animal models highlights key considerations for therapeutic translation of genetic medicines.

PLoS One. 2025 Jun 24;20(6):e0317387. doi: 10.1371/journal.pone.0317387. eCollection 2025.

Electrophysiology in neuropathic pain: a bibliometric analysis and literature review.

Front Neurosci. 2025 Jun 3;19:1616973. doi: 10.3389/fnins.2025.1616973. eCollection 2025.

Unlocking the potential: advancements and applications of gene therapy in severe disorders.

Ann Med. 2025 Dec;57(1):2516697. doi: 10.1080/07853890.2025.2516697. Epub 2025 Jun 17.

Targeting long non-coding RNA RP11-502I4.3 inhibits the trend of angiogenesis in diabetic retinopathy.

PLoS One. 2025 May 14;20(5):e0312791. doi: 10.1371/journal.pone.0312791. eCollection 2025.

Tackling visual impairment: emerging avenues in ophthalmology.

Front Med (Lausanne). 2025 Apr 28;12:1567159. doi: 10.3389/fmed.2025.1567159. eCollection 2025.

Perfusion-Based Production of rAAV via an Intensified Transient Transfection Process.

Biotechnol Bioeng. 2025 Jun;122(6):1424-1440. doi: 10.1002/bit.28967. Epub 2025 Mar 18.

Nucleic acid therapeutics: Past, present, and future.

Mol Ther Nucleic Acids. 2024 Dec 23;36(1):102440. doi: 10.1016/j.omtn.2024.102440. eCollection 2025 Mar 11.

Evaluation of subretinally delivered Cas9 ribonucleoproteins in murine and porcine animal models highlights key considerations for therapeutic translation of genetic medicines.

bioRxiv. 2024 Dec 30:2024.12.30.630799. doi: 10.1101/2024.12.30.630799.

Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: A comprehensive review.

Mol Ther. 2024 Dec 4;32(12):4185-4207. doi: 10.1016/j.ymthe.2024.10.017. Epub 2024 Oct 28.

本文引用的文献

Gene therapy 'cure' for blindness wanes.

Nat Biotechnol. 2015 Jul;33(7):678. doi: 10.1038/nbt0715-678.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

First AAV gene therapy poised for landmark approval.

Nat Biotechnol. 2017 Nov 9;35(11):998-999. doi: 10.1038/nbt1117-998.

Emerging Gene Therapy Treatments for Inherited Retinal Diseases.

Ophthalmic Surg Lasers Imaging Retina. 2018 Jul 1;49(7):472-478. doi: 10.3928/23258160-20180628-02.

Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.

Med Lett Drugs Ther. 2018 Mar 26;60(1543):53-55.

Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.

Mol Ther. 2021 Feb 3;29(2):442-463. doi: 10.1016/j.ymthe.2020.11.029. Epub 2020 Dec 3.

Quantitative Autofluorescence Following Gene Therapy With Voretigene Neparvovec.

JAMA Ophthalmol. 2020 Aug 1;138(8):919-921. doi: 10.1001/jamaophthalmol.2020.2018.

Bilateral Subretinal Voretigene Neparvovec-rzyl (Luxturna) Gene Therapy.

Ophthalmol Retina. 2019 May;3(5):450. doi: 10.1016/j.oret.2019.02.007.

The new landscape of retinal gene therapy.

Am J Med Genet C Semin Med Genet. 2020 Sep;184(3):846-859. doi: 10.1002/ajmg.c.31842. Epub 2020 Sep 5.

Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.

Mol Ther. 2018 Jan 3;26(1):256-268. doi: 10.1016/j.ymthe.2017.09.014. Epub 2017 Sep 19.

[RPE65-retinal Dystrophies: From the Spectrum of the Clinical Picture to Gene Therapy].

Klin Monbl Augenheilkd. 2024 Mar;241(3):257-258. doi: 10.1055/a-2237-7300. Epub 2024 Mar 20.

Gene therapy for eye as regenerative medicine? Lessons from RPE65 gene therapy for Leber's Congenital Amaurosis.

Int J Biochem Cell Biol. 2014 Nov;56:153-7. doi: 10.1016/j.biocel.2014.09.022. Epub 2014 Oct 5.

引用本文的文献

Trends and challenges of AAV-delivered gene editing therapeutics for CNS disorders: Implications for neurodegenerative disease.

Mol Ther Nucleic Acids. 2025 Jul 17;36(3):102635. doi: 10.1016/j.omtn.2025.102635. eCollection 2025 Sep 9.

Evaluation of subretinally delivered Cas9 ribonucleoproteins in murine and porcine animal models highlights key considerations for therapeutic translation of genetic medicines.

PLoS One. 2025 Jun 24;20(6):e0317387. doi: 10.1371/journal.pone.0317387. eCollection 2025.

Electrophysiology in neuropathic pain: a bibliometric analysis and literature review.

Front Neurosci. 2025 Jun 3;19:1616973. doi: 10.3389/fnins.2025.1616973. eCollection 2025.

Unlocking the potential: advancements and applications of gene therapy in severe disorders.

Ann Med. 2025 Dec;57(1):2516697. doi: 10.1080/07853890.2025.2516697. Epub 2025 Jun 17.

Targeting long non-coding RNA RP11-502I4.3 inhibits the trend of angiogenesis in diabetic retinopathy.

PLoS One. 2025 May 14;20(5):e0312791. doi: 10.1371/journal.pone.0312791. eCollection 2025.

Tackling visual impairment: emerging avenues in ophthalmology.

Front Med (Lausanne). 2025 Apr 28;12:1567159. doi: 10.3389/fmed.2025.1567159. eCollection 2025.

Perfusion-Based Production of rAAV via an Intensified Transient Transfection Process.

Biotechnol Bioeng. 2025 Jun;122(6):1424-1440. doi: 10.1002/bit.28967. Epub 2025 Mar 18.

Nucleic acid therapeutics: Past, present, and future.

Mol Ther Nucleic Acids. 2024 Dec 23;36(1):102440. doi: 10.1016/j.omtn.2024.102440. eCollection 2025 Mar 11.

Evaluation of subretinally delivered Cas9 ribonucleoproteins in murine and porcine animal models highlights key considerations for therapeutic translation of genetic medicines.

bioRxiv. 2024 Dec 30:2024.12.30.630799. doi: 10.1101/2024.12.30.630799.

Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: A comprehensive review.

Mol Ther. 2024 Dec 4;32(12):4185-4207. doi: 10.1016/j.ymthe.2024.10.017. Epub 2024 Oct 28.

本文引用的文献

Gene therapy 'cure' for blindness wanes.

Nat Biotechnol. 2015 Jul;33(7):678. doi: 10.1038/nbt0715-678.

Suppr超能文献

First AAV gene therapy poised for landmark approval.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译